Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[64Cu] Macrin PET Imaging in Healthy Volunteers and Patients with Inflammatory Diseases
NCT04843891Phase 1Unknown
- Start
- Sep 2021
- Primary completion
- Apr 2023
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of [64Cu] Macrin in cancer, sarcoidosis and myocardial infarction (MI) (4 arms). Primary endpoints: Human Dosimetry of [64Cu] Macrin at 1 year, [64Cu] Macrin Accumulation and Detection in Cancer at 1 year and 2 more. Status: unknown.
02
Drugs
[64Cu] Macrin
03
Conditions
cancersarcoidosismyocardial infarction (MI)
Beyond the preview
Go deeper on NCT04843891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843891.